Use of turbidimetric growth curves for early determination of antifungal drug resistance of filamentous fungi

被引:37
作者
Meletiadis, J
te Dorsthorst, DTA
Verweij, PE
机构
[1] Univ Nijmegen, Med Ctr, Dept Med Microbiol, NL-6500 HB Nijmegen, Netherlands
[2] Canisius Wilhelmina Hosp, Dept Med Microbiol & Infect Dis, Nijmegen, Netherlands
[3] Univ Nijmegen, Ctr Infect Dis, NL-6500 HB Nijmegen, Netherlands
关键词
D O I
10.1128/JCM.41.10.4718-4725.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A previously described microbroth kinetic system (J. Meletiadis, J. F. Meis, J. W. Mouton, and P. E. Verweij, J. Clin. Microbiol. 39:478-484,2001) based on continuous monitoring of changes in the optical density of fungal growth was used to describe turbidimetric growth curves of different filamentous fungi in the presence of increasing concentrations of antifungal drugs. Therefore, 24 clinical mold isolates, including Rhizopus oryzae, Aspergillus fumigatus, Aspergillus flavus, and Scedosporium prolificans, were tested against itraconazole, terbinafine, and amphotericin B according to NCCLS guidelines. Among various parameters of the growth curves, the duration of the lag phase was strongly affected by the presence of antifungal drugs. Exposure to increasing drug concentrations resulted in prolonged lag phases of the turbidimetric growth curves. The lag phases of the growth curves at drug concentrations which resulted in more than 50% growth (for itraconazole and terbinafine) and more than 75% growth (for amphotericin B) after 24 h of incubation for R. oryzae, 48 h for Aspergillus spp., and 72 h for S. prolificans Were 4 h longer than the lag phases of the growth curves at the corresponding drug-free growth controls which varied from 4.4 h for R. oryzae, 6.5 It for A. flavus, 7.9 h for A. fumigatus, and 11.6 h for S. prolificans. The duration of the lag phases showed small experimental and interstrain variability, with differences of less than 2 h in most of the cases. Using this system, itraconazole and terbinafine resistance (presence of >50% growth) as well as amphotericin B resistance (presence of >75% growth) was determined within incubation periods of 5.0 to 7.7 h for R. oryzae (for amphotericin B resistance incubation for up to 12 h was required), 8.8 to 11.4 h for A. fumigatus, 6.7 to 8.5 h for A. flavus, and 13 to 15.6 h for S. prolificans while awaiting formal MIC determination by the NCCLS reference method.
引用
收藏
页码:4718 / 4725
页数:8
相关论文
共 38 条
[1]   Conidial viability assay for rapid susceptibility testing of Aspergillus species [J].
Balajee, SA ;
Marr, KA .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (08) :2741-2745
[2]   Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients [J].
Caillot, D ;
Mannone, L ;
Cuisenier, B ;
Couaillier, JF .
CLINICAL MICROBIOLOGY AND INFECTION, 2001, 7 :54-61
[3]   Evaluation of a capacitance method for direct antifungal susceptibility testing of yeasts in positive blood cultures [J].
Chang, HC ;
Chang, JJ ;
Huang, AH ;
Chang, TC .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (03) :971-976
[4]   Use of spectrophotometric reading for in vitro antifungal susceptibility testing of Aspergillus spp. [J].
Dannaoui, E ;
Persat, F ;
Monier, MF ;
Borel, E ;
Piens, MA ;
Picot, S .
CANADIAN JOURNAL OF MICROBIOLOGY, 1999, 45 (10) :871-874
[5]   In vitro susceptibilities of zygomycetes to conventional and new antifungals [J].
Dannaoui, E ;
Meletiadis, J ;
Mouton, JW ;
Meis, JFGM ;
Verweij, PE .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (01) :45-52
[6]   Acquired itraconazole resistance in Aspergillus fumigatus [J].
Dannaoui, E ;
Borel, E ;
Monier, MF ;
Piens, MA ;
Picot, S ;
Persat, F .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (03) :333-340
[7]   Itraconazole resistance in Aspergillus fumigatus [J].
Denning, DW ;
Venkateswarlu, K ;
Oakley, KL ;
Anderson, MJ ;
Manning, NJ ;
Stevens, DA ;
Warnock, DW ;
Kelly, SL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) :1364-1368
[8]   Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection [J].
Denning, DW ;
Radford, SA ;
Oakley, KL ;
Hall, L ;
Johnson, EM ;
Warnock, DW .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (03) :401-414
[9]   Therapeutic outcome in invasive aspergillosis [J].
Denning, DW .
CLINICAL INFECTIOUS DISEASES, 1996, 23 (03) :608-615
[10]  
DENNING DW, 1990, REV INFECT DIS, V12, P1147